J. Goldman & Co’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

J. Goldman & Co’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-72,598	Closed	-$1.38M	–	448
2018 Q1	$1.38M	Buy	+72,598	New	+$1.55M	0.06%	245

Other funds holding SGMO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

J. Goldman & Co's SGMO Position: Q2 2018 in Review

J. Goldman & Co sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2018, closing a stake of 72,598 shares — an estimated $1.38M sold.

J. Goldman & Co first reported a position in SGMO in Q1 2018 and held it in 1 quarter. The position peaked at $1.38M in Q1 2018. 210 funds tracked by Wall St. Rank hold SGMO as of Q2 2018.

J. Goldman & Co reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2018 after selling out during the quarter.
J. Goldman & Co sold 72,598 SANGAMO THERAPEUTICS INC shares in Q2 2018, an estimated $1.38M.
J. Goldman & Co first reported a position in SANGAMO THERAPEUTICS INC in Q1 2018 and held it in 1 quarter.
J. Goldman & Co's SANGAMO THERAPEUTICS INC position peaked at $1.38M in Q1 2018.
210 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2018.

Based on J. Goldman & Co's 13F filing for Q2 2018, filed 14 Aug 2018.